The International Telecom Community Awarded Nexign Microservices Platform Twice in a Week
Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced it won the MEA Technology Achievement Award and was shortlisted for another prestigious international award for the telecom industry, Glotel.
The MEA Tech Award was introduced by the MEA Business magazine, one of the business's top publications in the Middle East and Africa, while the Global Telecom Award brings together the top players in telecom from around the world recognizing innovation and excellence.
The prize and the nomination were awarded the same week for the Nexign Microservices Platform and the Microservices Factory project based on it.
Nexign Microservices Platform supports the whole cycle of development and delivery based on cloud-native microservices architecture, which lays the foundation for continuous creation of new digital services. The framework leverages CI/CD automation and facilitates partner collaboration through standardised APIs. This solution enabled the launch of Microservices Factory at MegaFon and allowed the company to reduce TTM for internal innovations. Nexign Microservices Framework empowered MegaFon to roll out 100+ new services, bring to market a multi-subscription digital services platform MegaFon Plus, and generally slash TTM from 3-4 months up to 2 weeks.
The project resulted in building the Open Ecosystem, constantly expanding with the new partners enriching MegaFon’s portfolio with the new product offerings. Nexign Microservices Platform enables telecom operators to always stay at the forefront of market changes and steadily cater to the ever-changing needs of its customers.
Both the development project and the final product have garnered recognition from the international telecom industry, to which the MEA Tech Award and the Glotel nomination are a token.
“The award and the nomination are not just a huge honour for Nexign. They signify the professional community’s recognition and appreciation of our projects. We strongly believe the Microservices Platform is a solution the world of telecom really needs these days. It would allow CSPs to swiftly react to any challenges the market can throw at them,” says Dmitry Antipov, the Customer Relations Director at Nexign.
About Nexign
Nexign (a part of Intellectual Computer Systems Holding (ICS Holding) is a major supplier of BSS solutions for telecom operators across 17 countries. The company focuses on modernising CSP’s IT systems to boost their profitability and slash TTM for new products.
Over 30 years on the market, Nexign has created an extensive suite of technological solutions to support and sustain transformation of telecom operators. Nexign’s products range from convergent BSS systems to elaborate optimisation solutions for subordinate software. Nexign boasts its comprehensive approach to reorganising all kinds of processes in the telecom industry, which offers a fresh impetus to the customer business and encourages innovations.
For more information, please visit the website and follow the latest news from Nexign on Twitter, Facebook and LinkedIn.
About ICS Holding
Intellectual Computer Systems Holding (https://x-holding.ru/) is a multidisciplinary Russian IT group, which holds a leading position in the technology and IT services development market. ICS Holding is the largest IT provider for telecom operators and one of the fastest growing IT holdings in the Russian market. ICS Holding is among Russia’s top three largest IT development companies, top ten IT companies and top ten suppliers of equipment for the industrial sector. The holding brings together more than 30 companies united in five subholdings: YADRO, Nexign, Citadel, Kryptonit and Forpost.
ICS Holding’s top priorities include the digital transformation of enterprise companies, information security, data storage systems, cryptography and quantum computing, machine learning and artificial neural networks, blockchain technology and artificial intelligence (AI). In terms of geographical reach, the business covers all regions of Russia, as well as several countries in the CIS and further afield.
ICS Holding companies employ in excess of 6,000 people. More than 120 global projects have been implemented in Russia and worldwide. More than 1000 of ICS Holding’s customers work in more than 20 countries.
The total revenue of ICS Holding companies in 2020 reached 85 billion rubles. The partner network of ICS Holding includes more than 50 companies in Russia and beyond.
15.09.2020 ICS Holding became a part of USM Telecom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005212/en/
Contact information
Galiya Sayfutdinova
Marketing Communications Team Lead, Nexign
galiya.sayfutdinova@nexign.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom